BACKGROUND: Concomitant hepatitis C virus infection (HCV) needs caution when selecting systemic treatments in psoriasis patients as some agents confer a risk of liver toxicity and/or are immunosuppressant. Phototherapy may provide a therapeutic choice but it is not always a practical option. Limited evidence supports the use of cyclosporine or TNF-alpha blockers. No data are available concerning the safety of efalizumab in patients with HCV infection. OBJECTIVE: To describe the clinical characteristics and evolution of 5 adult patients with severe chronic plaque psoriasis and concomitant HCV infection who were treated with efalizumab. METHOD: A retrospective clinical case report. RESULTS: Five adult patients with severe chronic plaque psoriasis and concomitant HCV infection were treated successfully using efalizumab with no increased viral replication and progression of liver disease for a follow-up of 8-20 months. CONCLUSION: Although further confirmation is needed, this report provides preliminary evidence to support also a cautious use of efalizumab in patients with HCV infection

Treatment of psoriasis with efalizumab in patients with hepatitis C viral infection: report of five cases

GROSSI, PAOLO ANTONIO;
2009-01-01

Abstract

BACKGROUND: Concomitant hepatitis C virus infection (HCV) needs caution when selecting systemic treatments in psoriasis patients as some agents confer a risk of liver toxicity and/or are immunosuppressant. Phototherapy may provide a therapeutic choice but it is not always a practical option. Limited evidence supports the use of cyclosporine or TNF-alpha blockers. No data are available concerning the safety of efalizumab in patients with HCV infection. OBJECTIVE: To describe the clinical characteristics and evolution of 5 adult patients with severe chronic plaque psoriasis and concomitant HCV infection who were treated with efalizumab. METHOD: A retrospective clinical case report. RESULTS: Five adult patients with severe chronic plaque psoriasis and concomitant HCV infection were treated successfully using efalizumab with no increased viral replication and progression of liver disease for a follow-up of 8-20 months. CONCLUSION: Although further confirmation is needed, this report provides preliminary evidence to support also a cautious use of efalizumab in patients with HCV infection
2009
Psoriasis Efalizumab Hepatitis C virus infection
Gisondi, P; Prignano, F; Grossi, PAOLO ANTONIO; Lotti, T; Girolomoni, G.
File in questo prodotto:
File Dimensione Formato  
Gisondi_Dermatology.pdf

non disponibili

Tipologia: Documento in Post-print
Licenza: DRM non definito
Dimensione 314.93 kB
Formato Adobe PDF
314.93 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11383/1743330
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 5
social impact